Aardvark Therapeutics (AARD) Competitors $11.26 +0.06 (+0.54%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. VERV, LENZ, PRAX, RCUS, AVXL, GPCR, SYRE, CRON, ELVN, and AKBAShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Cronos Group (CRON), Enliven Therapeutics (ELVN), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Verve Therapeutics LENZ Therapeutics Praxis Precision Medicines Arcus Biosciences Anavex Life Sciences Structure Therapeutics Spyre Therapeutics Cronos Group Enliven Therapeutics Akebia Therapeutics Aardvark Therapeutics (NASDAQ:AARD) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership. Which has higher earnings & valuation, AARD or VERV? Aardvark Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/A-$20.59MN/AN/AVerve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27 Is AARD or VERV more profitable? Aardvark Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -303.64%. Aardvark Therapeutics' return on equity of 0.00% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Verve Therapeutics -303.64%-35.81%-27.57% Do analysts prefer AARD or VERV? Aardvark Therapeutics presently has a consensus target price of $32.80, suggesting a potential upside of 191.30%. Verve Therapeutics has a consensus target price of $14.57, suggesting a potential upside of 30.92%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Verve Therapeutics 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders and institutionals have more ownership in AARD or VERV? 97.1% of Verve Therapeutics shares are owned by institutional investors. 19.3% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor AARD or VERV? In the previous week, Aardvark Therapeutics had 8 more articles in the media than Verve Therapeutics. MarketBeat recorded 10 mentions for Aardvark Therapeutics and 2 mentions for Verve Therapeutics. Verve Therapeutics' average media sentiment score of 0.00 beat Aardvark Therapeutics' score of -0.15 indicating that Verve Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Verve Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAardvark Therapeutics beats Verve Therapeutics on 8 of the 12 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$244.30M$3.08B$5.58B$9.81BDividend YieldN/A2.27%4.60%4.10%P/E RatioN/A20.5630.2825.72Price / SalesN/A191.82388.6180.21Price / CashN/A42.0537.7558.93Price / BookN/A7.598.456.01Net Income-$20.59M-$54.65M$3.25B$265.06M7 Day Performance-5.93%5.43%4.05%2.80%1 Month Performance-7.02%6.75%4.32%1.68%1 Year PerformanceN/A31.59%36.25%29.59% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$11.26+0.5%$32.80+191.3%N/A$244.30MN/A0.0018News CoverageEarnings ReportAnalyst ForecastLockup ExpirationGap UpVERVVerve Therapeutics2.9437 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics1.1322 of 5 stars$34.28+6.7%$49.60+44.7%+69.9%$977.59M$5M-18.04110High Trading VolumePRAXPraxis Precision Medicines1.8494 of 5 stars$45.89-2.9%$95.22+107.5%-6.1%$965.98M$8.55M-3.73110Analyst RevisionGap DownRCUSArcus Biosciences2.3682 of 5 stars$9.06-2.4%$21.14+133.4%-35.7%$959.36M$258M-2.86500Analyst RevisionAVXLAnavex Life Sciences3.8161 of 5 stars$11.01-1.9%$44.00+299.6%+64.5%$940.47MN/A-20.0240News CoverageEarnings ReportAnalyst ForecastGPCRStructure Therapeutics2.4576 of 5 stars$16.29+0.5%$75.71+364.9%-44.2%$933.83MN/A-15.51136Analyst RevisionSYRESpyre Therapeutics3.0911 of 5 stars$15.29+0.3%$53.40+249.2%-31.2%$922.28M$890K-4.5073Positive NewsCRONCronos Group0.874 of 5 stars$2.31+1.5%N/A+12.4%$884.68M$117.61M17.73450Earnings ReportAnalyst RevisionGap DownELVNEnliven Therapeutics2.8863 of 5 stars$17.93+0.1%$41.20+129.8%-7.1%$879.58MN/A-9.3450News CoverageEarnings ReportInsider TradeAKBAAkebia Therapeutics4.067 of 5 stars$3.29+9.1%$6.75+105.5%+146.3%$868.03M$160.18M-15.74430 Related Companies and Tools Related Companies VERV Alternatives LENZ Alternatives PRAX Alternatives RCUS Alternatives AVXL Alternatives GPCR Alternatives SYRE Alternatives CRON Alternatives ELVN Alternatives AKBA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access